Home Stock Ideas Long Ideas Healthcare  Summary I believe my original bull case on Roivant Sciences has largely played out, with the stock up sharply since my initial coverage. Brepocitinib is clearly now becoming a broader immunology franchise across DM, NIU, CS, and LPP. ROIV also settled with Moderna regarding LNP, which adds to its already cash-rich balance sheet and supports its ongoing buybacks and pipeline. However, ROIV’s valuation is at a premium, which has reduced its margin of safety and highlights the remaining execution risks going forward. Despite these caveats, ROIV remains attractive for patient, long-term investors who are betting on management pivoting from seeking M&A deals to growing revenues. Solskin/DigitalVision via Getty Images Roivant Sciences Ltd. ( ROIV ) is a late-stage biotechnology company that operates through subsidiaries called Vants. Its current pipeline is centered on immunology and specialty diseases.…